Selected characteristics in younger (age < 61 years) AML patients with MK according to treatment strategy (n = 163)
| Characteristics . | Allogeneic HSCT from MRD, n (%) . | Allogeneic HSCT from MUD, n (%) . | No HSCT, n (%) . | P . |
|---|---|---|---|---|
| Sex | ||||
| Male | 17 (55) | 41 (57) | 37 (57) | .99 |
| Female | 14 (45) | 31 (43) | 28 (43) | |
| Median age, y (range) | 49 (19-59) | 51 (23-61) | 55 (27-61) | .002 |
| WBC | .33 | |||
| Median (range) | 6.2 (1.8-108) | 8.0 (0.9-210) | 5.0 (0.5-533) | |
| No. missing | 0 | 0 | 0 | |
| Percentage of PB blasts | .51 | |||
| Median (range) | 24 (0-91) | 35 (0-99) | 34 (0-94) | |
| No. missing | 4 | 2 | 4 | |
| Percentage of BM blasts | .69 | |||
| Median (range) | 61 (21-100) | 65 (8-99) | 68 (15-100) | |
| No. missing | 2 | 7 | 3 | |
| Type of AML | .08 | |||
| De novo | 20 (65) | 60 (83) | 54 (83) | |
| s-/t-AML | 11 (35) | 12 (17) | 11 (17) | |
| Complex karyotype* | 18 (58) | 53 (74) | 50 (77) | .15 |
| MDS-related cytogenetic abnormalities† | 24 (77) | 56 (78) | 52 (80) | .94 |
| Response to induction | 16 (52) | 41 (57) | 25 (38) | .09 |
| Characteristics . | Allogeneic HSCT from MRD, n (%) . | Allogeneic HSCT from MUD, n (%) . | No HSCT, n (%) . | P . |
|---|---|---|---|---|
| Sex | ||||
| Male | 17 (55) | 41 (57) | 37 (57) | .99 |
| Female | 14 (45) | 31 (43) | 28 (43) | |
| Median age, y (range) | 49 (19-59) | 51 (23-61) | 55 (27-61) | .002 |
| WBC | .33 | |||
| Median (range) | 6.2 (1.8-108) | 8.0 (0.9-210) | 5.0 (0.5-533) | |
| No. missing | 0 | 0 | 0 | |
| Percentage of PB blasts | .51 | |||
| Median (range) | 24 (0-91) | 35 (0-99) | 34 (0-94) | |
| No. missing | 4 | 2 | 4 | |
| Percentage of BM blasts | .69 | |||
| Median (range) | 61 (21-100) | 65 (8-99) | 68 (15-100) | |
| No. missing | 2 | 7 | 3 | |
| Type of AML | .08 | |||
| De novo | 20 (65) | 60 (83) | 54 (83) | |
| s-/t-AML | 11 (35) | 12 (17) | 11 (17) | |
| Complex karyotype* | 18 (58) | 53 (74) | 50 (77) | .15 |
| MDS-related cytogenetic abnormalities† | 24 (77) | 56 (78) | 52 (80) | .94 |
| Response to induction | 16 (52) | 41 (57) | 25 (38) | .09 |
AML indicates acute myeloid leukemia; MDS, myelodysplastic syndrome; MRD, matched related donor; MUD, matched unrelated donor; PB, peripheral blood; s-AML, secondary AML; t-AML, therapy-related AML; and WBC, white blood count. Percentages may not add to 100 because of rounding.
According to Döhner et al.6
According to Swerdlow et al.3